Genomes and Genes
Francois Xavier Mahon
- [Chronic myeloid leukemia and tyrosine kinase inhibitors]F X Mahon
Laboratoire de Greffe de Moelle, Universite Victor Segalen, UMR CNRS 5540, 146, rue Leo Saignat, 33076 Bordeaux, France
Rev Med Interne 22:894-9. 2001....
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trialFrancois Xavier Mahon
Laboratoire d Hématologie et Service des Maladies du Sang, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
Lancet Oncol 11:1029-35. 2010..We aimed to assess whether imatinib can be discontinued without occurrence of molecular relapse in patients in complete molecular remission (CMR) while on imatinib...
- JAK the triggerFrancois Xavier Mahon
Laboratoire d hématopoïèse leucémique et cible thérapeutique, Universite Victor Segalen Bordeaux 2, INSERM E0217, 33076 Bordeaux Cedex, France
Oncogene 24:7125-6. 2005....
- MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line modelsFrancois Xavier Mahon
Laboratoire Greffe de Moelle, Universite Victor Segalen, Bordeaux, France
Blood 101:2368-73. 2003..The possible role of MDR overexpression in clinical resistance to imatinib remains to be defined. We therefore confirm that imatinib should be added to the extensive list of drugs that can be affected by the MDR phenomenon...
- [Leucemogenesis of chronic myelogenous leukemia]Francois Xavier Mahon
Laboratoire d Hematologie, CHU de Bordeaux, INSERM E0217, Universite Victor Segalen Bordeaux 2, 33076 Bordeaux Cedex
Rev Prat 55:1642-6. 2005..These new specific drugs and their effects on the chronic myelogenous leukemia must be taken into account to explain the physiopathology of the disease...
- Pharmacologic monitoring and determinants of intracytoplasmic drug levelsFrancois Xavier Mahon
Laboratoire Hématopoïèse Leucémique et Cible Thérapeutique, Inserm U876, Universite Victor Segalen Bordeaux 2, 146, rue Leo Saignat 33076, Bordeaux Cedex, France
Best Pract Res Clin Haematol 22:381-6. 2009....
- Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cellsVanessa Desplat
Laboratoire Hématopoïèse Normale et Pathologique, FRE CNRS 2617, Universite Victor Segalen, rue Leo Saignat, 33076 Bordeaux Cedex, France
Cytometry A 62:35-45. 2004..In this study, we developed a method to detect the phosphotyrosine proteins by flow cytometry and we asked whether phosphorylation was affected by imatinib mesylate treatment...
- A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinibVanessa Augis
Université Bordeaux Segalen and INSERM U1035 Bordeaux, Bordeaux, France Laboratoire d hématologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
PLoS ONE 8:e78582. 2013..The present study aimed at identifying mutations in the BIM sequence that could lead to imatinib resistance independently of BCR-ABL mutations...
- ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinibKelly Airiau
Laboratoire d Hématopoïèse Leucémique et Cibles Thérapeutiques, INSERM 1035, Université Bordeaux Segalen, Bordeaux Cedex, France
Exp Hematol 40:367-78.e2. 2012..Interestingly, a lethal effect was also observed in the more immature CD34(+)CD38(-) TKI-insensitive population. Combination therapy might by an interesting strategy for the treatment of CML patients...
- Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell linesVanessa Desplat
Laboratoire Hematopoïése normale et pathologique FRE CNRS 2617, Universite Victor Segalen, Bordeaux Cedex, France
Cancer 103:102-10. 2005..Resistance to imatinib is currently the most important concern of this treatment. One of the main mechanisms of this resistance is overexpression of BCR-ABL...
- Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokinesFrancis Belloc
Laboratoire d Hematologie, Hopital du Haut leveque, Pessac, France
Cancer Biol Ther 6:912-9. 2007..Thus BCR-ABL inhibition restores the cytokine dependence but is not sufficient to induce apoptosis when other signaling pathways are activated...
- Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratoryStephane Bouchet
Univ Bordeaux, F 33000, Bordeaux, France INSERM U657, F 33000, Bordeaux, France CHU Bordeaux, F 33000, Bordeaux, France
Fundam Clin Pharmacol 27:690-7. 2013..69 and 2.08, respectively. These data support in real-life setting that imatinib C(min) threshold of 1000 ng/mL is associated with major and complete molecular response and that TDM could play an important role in dose optimization...
- Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometryKarine Titier
Department of Clinical Pharmacology and Toxicology, Pellegrin Hospital and University Victor Segalen, 33076 Bordeaux, France
Ther Drug Monit 27:634-40. 2005..It can be used to evaluate patient adherence to daily oral therapy, drug-drug interactions, or pharmacokinetic/pharmacodynamic relationships...
- Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemiaStéphanie Dulucq
Laboratoire Hématopoïèse Leucémique et Cible Thérapeutique, Universite Victor Segalen Bordeaux 2, Inserm U876, Bordeaux, France
Blood 112:2024-7. 2008..6%; P = .021). Hence, we demonstrated the usefulness of these single nucleotide polymorphisms in the identification of CML who may or may not respond optimally to imatinib...
- Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571Christophe Barthe
Laboratoire de Greffe de Moelle et Laboratoire d hématologie, Université Victor Segalen and Service des Maladies du Sang, CHU de Bordeaux, Bordeaux, France
Br J Haematol 119:109-11. 2002..We suggest that the acquisition of point-mutations in the tyrosine kinase domain of Bcr-Abl may cause progressive clinical resistance to STI571...
- Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cellsRomain Gioia
Hématopoïèse Leucémique et Cible Thérapeutique, Inserm U1035, Universite Victor Segalen, Bordeaux, France
Blood 118:2211-21. 2011..We conclude that an oncogenic signaling mediated by Lyn and Syk can bypass the need of Bcr-Abl in CML cells. Thus, targeting these kinases may be of therapeutic value to override imatinib or nilotinib resistance in CML...
- Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpressionFrancois Xavier Mahon
Hématopoïèse Leucémique et Cible Thérapeutique, Inserm U876, Universite Victor Segalen, Laboratoire d hématologie CHU de Bordeaux, Bordeaux Cedex, France
Cancer Res 68:9809-16. 2008..Such mechanisms of resistance are close to those observed in imatinib-resistant cell lines and emphasize the critical role of Lyn in nilotinib resistance...
- Proteomic analysis of an imatinib-resistant K562 cell line highlights opposing roles of heat shock cognate 70 and heat shock 70 proteins in resistanceMarion Pocaly
U876 INSERM, Universite Victor Segalen Bordeaux 2, Hématopoïèse Leucémique et Cibles Thérapeutiques, Bordeaux, France
Proteomics 8:2394-406. 2008..In contrast, the induced decreased expression of Hsc70 was accompanied by a greater overexpression of Hsp70. This proteomic study therefore suggests opposing roles of Hsp70 and Hsc70 in imatinib resistance...
- A SIN lentiviral vector containing PIGA cDNA allows long-term phenotypic correction of CD34+-derived cells from patients with paroxysmal nocturnal hemoglobinuriaDavid Robert
INSERM E 0217, Laboratoire de Pathologie Moléculaire et Thérapie Génique, Universite Victor Segalen Bordeaux 2, 146 rue Leo Saignat, 33076 Bordeaux, France
Mol Ther 7:304-16. 2003..This expression was stable during erythroid, myeloid, and megakaryocytic liquid culture differentiation. CD59 surface cell expression was fully restored during 5 weeks of long-term culture...
- Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatmentMarie Colombat
Laboratoire d hématologie Université Victor Segalen, Bordeaux, France
Haematologica 91:162-8. 2006..However, the ultimate goal of therapy for CML is complete elimination of Philadelphia chromosome positive cells or BCR-ABL rearrangements. We studied molecular responses in CML patients in CCR after imatinib treatment...
- Imatinib plus peginterferon alfa-2a in chronic myeloid leukemiaClaude Preudhomme
Laboratoire d Hematologie, Centre Hospitalier Universitaire de Lille, and INSERM Unité 837, Lille, France
N Engl J Med 363:2511-21. 2010..However, only a minority of patients treated with imatinib have a complete molecular remission...
- Phosphorylation of serine palmitoyltransferase long chain-1 (SPTLC1) on tyrosine 164 inhibits its activity and promotes cell survivalSaid Taouji
Inserm U1053, 33076 Bordeaux, France
J Biol Chem 288:17190-201. 2013..Our observations provide a mechanistic explanation for imatinib-mediated cell death and a novel avenue for therapeutic strategies...
- Hypoxia modifies proliferation and differentiation of CD34(+) CML cellsVanessa Desplat
Laboratoire de Greffe de Moelle, Universite Bordeaux 2, Bordeaux, France
Stem Cells 20:347-54. 2002..These effects could be linked to inhibition by hypoxia of the tyrosine hyperphosphorylation of cellular proteins, a major hallmark of CML cells...
- [Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia]G Etienne
Laboratoire de Greffe de Moelle, , 146, , 33076 Bordeaux, France
Bull Cancer 88:651-8. 2001..STI571 is an original therapeutic approach which may be used as a model for the development of other drugs in cancer...
- Is going for cure in chronic myeloid leukemia possible and justifiable?Francois Xavier Mahon
Laboratoire d Hematologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux Cedex, France
Hematology Am Soc Hematol Educ Program 2012:122-8. 2012..If we win this battle, this progress will certainly benefit the treatment and management of other leukemias and solid tumors and will validate this new topic...
- Mycophenolic Acid overcomes imatinib and nilotinib resistance of chronic myeloid leukemia cells by apoptosis or a senescent-like cell cycle arrestClaire Drullion
Laboratoire Hématopoïèse Leucémique et Cibles Thérapeutiques, Inserm U1035, Université Bordeaux Segalen, 146 Rue Léo Saignat Bat TP 4e étage, 33076 Bordeaux, France
Leuk Res Treatment 2012:861301. 2012..These results show that MPA is an interesting tool to overcome resistance in vitro and in vivo mainly in the evolved phase of the disease...
- A method to measure deferasirox in plasma using HPLC coupled with MS/MS detection and its potential applicationEmmanuelle Chauzit
Département de Pharmacologie Clinique et Toxicologie, CHU de Bordeaux, Bordeaux, France
Ther Drug Monit 32:476-81. 2010..It allows evaluation of patient compliance, drug-drug interactions, and further investigations of pharmacokinetic/pharmacodynamic relationships...
- Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cellsKelly Airiau
Laboratoire d Hématopoïèse Leucémique et Cibles Thérapeutiques, INSERM 1035, Universite Bordeaux, Bordeaux, France
Oncotarget 7:845-59. 2016..So, this combination of a MAP Kinase pathway inhibitor and a BH3 mimetic could be a promising strategy to improve the treatment of AML. ..
- Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemiaStephane Picard
Department of Clinical Pharmacology and Toxicology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
Blood 109:3496-9. 2007..Therefore, monitoring of imatinib plasma levels could be very useful for the management of patients with CML or should at least be checked in the case of treatment failure or suboptimal response...
- Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cellsArnaud Pigneux
CHU Bordeaux, Hopital Haut Leveque, Laboratoire d Hematologie, Pessac, France
Exp Hematol 36:1648-59. 2008..Triptolide has shown antitumor activity in a broad range of solid tumors and on leukemic cells in vitro...
- Expression of Flt3-ligand by the endothelial cellA Solanilla
Laboratoire de Greffe de Moelle, Universite Victor Segalen, Bordeaux, France
Leukemia 14:153-62. 2000..This stimulation is essential to explain their modulatory effect on the generation of clonogenic cells in cocultures EC/hematopoietic progenitors. Leukemia (2000) 14, 153-162...
- ELN 2013 response status criteria: relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?Gabriel Etienne
Hematology Department, Institut Bergonie, Bordeaux, France
Am J Hematol 90:37-41. 2015..However, in our patient population this improvement is related to a better definition of failure rather than that of optimal response for CP-CML patients treated with IM frontline therapy...
- Variable behavior of iPSCs derived from CML patients for response to TKI and hematopoietic differentiationAurélie Bedel
Inserm U1035, Biothérapies des maladies génétiques et cancers, Bordeaux, France Université Bordeaux Segalen, Bordeaux, France
PLoS ONE 8:e71596. 2013..Thus, several clones of CML-iPSCs are a powerful model to decipher all the mechanisms leading to LSC survival following TKI therapy and are a promising tool for testing new therapeutic agents...
- Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITDGaëlle Labouré
Service d Hématologie et de Thérapie Cellulaire, CHU Haut Levêque, Bordeaux, France
Biol Blood Marrow Transplant 18:1845-50. 2012..32; P = .01). A landmark analysis performed at day 185 after CR1 confirmed a lower CIR after allo. RIC-allo reduces the risk of relapse, suggesting a potent graft-versus-leukemia (GVL) effect in these patients at a high risk of relapse...
- Differential effect of interferon alpha on chronic myelogenous leukaemia and normal haematopoietic progenitors in a stromal cell co-culture context: role of the flt3 ligandA Solanilla
FR 60, Biologie des Greffes, Universite de Bordeaux 2, France
Br J Haematol 109:382-7. 2000....
- Ex vivo cytokine expansion of peripheral blood Ph-negative cells in chronic myeloid leukaemiaF X Mahon
Laboratoire de Greffe de Moelle, UMR CNRS 5540, FR60, Universite Victor Segalen Bordeaux 2, France
Leuk Lymphoma 32:151-7. 1998..Therefore ex vivo expansion of putatively normal hematopoietic progenitor cells from cytapheresis is feasible in CML...
- Expression of neurotrophins and their receptors in human bone marrowE Labouyrie
Laboratoire d Histologie Embryologie, Universite Victor Segalen, Bordeaux, France
Am J Pathol 154:405-15. 1999..The local expression of neurotrophin genes suggests a wide range of paracrine and/or autocrine mode of action through their corresponding receptors within the bone marrow...
- Increased liposome-mediated gene transfer into haematopoietic cells grown in adhesion to stromal or fibroblast cell line monolayersG Marit
Laboratoire de Greffe de Moelle, UMR CNRS 5540, Universite Victor Segalen Bordeaux 2, France
Eur J Haematol 64:22-31. 2000..30%) for the cell lines and 13.6% (range 8.2-24.2%) for CD34+ HPC. These results indicate that liposome-mediated transfection of HC is significantly increased when cells are grown in adherence to stroma or fibroblast monolayers...
- Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United StatesWilliam V Padula
Department of Health Policy and Management, Johns Hopkins University, Baltimore, MD WVP Department of Medicine RAL and Departments of Pediatrics and of Public Health Sciences RMC, University of Chicago, Chicago, IL Eshelman School of Pharmacy and Gillings School of Global Public Health, Lineberger Comprehensive Cancer Center, and Cecil G Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC SBD Department of Haematology, Hammersmith Hospital, Imperial College, London, UK JFA Department of Medicine RH, SS and Department of Hematology and Oncology MCM, University of Heidelberg, Mannheim, Germany Department of Haematology and Oncology, S Orsola Malpighi University Hospital MB, and Department of Hematology, L e A Seragnoli GM, University of Bologna, Bologna, Italy Department of Haematology and Oncology, University Hospital, Jena, Germany EE INSERM Centre d Investigation Clinique CIC 1402, CHU de Poitiers, Poitiers, France JG, FG Laboratoire d Hematologie, Universite Victor Segalen, Bordeaux, Pessac, France FXM Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic JM Department of Hematology and Oncology, University Hospital Leipzig, Leipzig
J Natl Cancer Inst 108:. 2016....
- Verification of a quantitative method: complete blood count by flow cytometry, the HematoFlowTM system (Beckman Coulter)Inès Vergnolle
Laboratoire d Hematologie, CHU de Bordeaux, Hopital Haut Leveque, Pessac, France
Ann Biol Clin (Paris) 74:617-631. 2016..Improvements in hematology disease diagnosis and follow-up were possible using this system. The laboratory has now entered in an accreditation procedure and needs to check this method in compliance with the COFRAC requirements...
- The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alphaJoerg Hasford
Universite Victor Segalen, Bordeaux, France University Hospital Groningen, Groningen, The Netherlands
Haematologica 90:335-40. 2005..MCR was defined as a reduction of Philadelphia chromosome-positive bone marrow cells to <or= 35%. The New CML score discriminated three risk groups with significantly different survival probabilities...
- The necrotic signal induced by mycophenolic acid overcomes apoptosis-resistance in tumor cellsGwendaline Guidicelli
CNRS UMR 5164, Bordeaux, France
PLoS ONE 4:e5493. 2009..The anti-viral agent ribavirin and the immunosuppressant mycophenolic acid (MPA) are potent inhibitors of IMPDH. We recently showed that IMPDH inhibition led to a necrotic signal requiring the activation of Cdc42...
- The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cellsF Belloc
Laboratoire d Hématopoïèse Leucémique et Cibles Thérapeutiques, Inserm U876, Universite Victor Segalen, Bordeaux Cedex, France
Leukemia 23:679-85. 2009..We conclude that the c-KIT pathway may substitute for BCR-ABL tyrosine kinase to activate survival signals, and that c-KIT must be inhibited besides Bcr-Abl to allow apoptosis of CML cells...
- Quantification of the Mutant CALR Allelic Burden by Digital PCR: Application to Minimal Residual Disease Evaluation after Bone Marrow TransplantationOlivier Mansier
Hematology Laboratory, CHU de Bordeaux, Bordeaux, France Leukemic Hematopoiesis and Therapeutic Targets Laboratory, Biothérapie des maladies génétiques et cancers, Universite de Bordeaux, Bordeaux, France
J Mol Diagn 18:68-74. 2016..In conclusion, digital PCR adapted to type 1 and 2 CALR mutations is an inexpensive, highly precise, and sensitive technique suitable for evaluation of myeloproliferative neoplasm patients during follow-up. ..
- Bundles of Auer rods in blast cells and mature neutrophils in a non-promyelocytic acute myeloblastic leukaemiaEstelle Guerin
Laboratoire d Hématologie du CHU de Bordeaux, Bordeaux, France
Br J Haematol 141:749. 2008
- The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneityChloe James
INSERM, U876, Bordeaux, France
Blood 112:2429-38. 2008..These experiments provide new insights into the pathogenesis of JAK2V617F MPD and demonstrate that a JAK2 inhibitor needs to target the HSC compartment for optimal disease control in classical MPD...
- Imatinib sensitizes T-cell lymphocytes from chronic myeloid leukemia patients to FasL-induced cell death: a brief communicationLaurence Legros
CNRS, Institute of Developmental Biology and Cancer Research Université de Nice, France
J Immunother 35:154-8. 2012....
- Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfaF X Mahon
Service des Maladies du Sang, Centre Hospitalier Universitaire de Bordeaux, Bordeaux 2, France
J Clin Oncol 20:214-20. 2002..In this population of patients, the question of whether treatment should then be withdrawn is not yet resolved...
- The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical studyA Soria
Inserm U876, University Victor Segalen Bordeaux 2, Bordeaux, France
Dermatology 216:109-17. 2008..Moreover, increased levels of PDGF and stimulatory autoantibodies to PDGFR have been identified in the serum of scleroderma patients...
- What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer?Matthieu Lewis
Laboratory of Mammary and Leukemic Oncogenesis Genetic Diversity and Resistance to Treatment, Action, INSERM U1218, University of Bordeaux, Bordeaux, Gironde, France
Hematol Oncol . 2016..One of the key issues is about the resistance of the leukemic stem cells to tyrosine kinase inhibitors. Here, we briefly describe our current studies on CML resistance, and leukemic stem cell modeling and characterization...
- Deep molecular responses for treatment-free remission in chronic myeloid leukemiaStéphanie Dulucq
Laboratoire d Hematologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
Cancer Med 5:2398-411. 2016..With an increasing number of ongoing TFR clinical trials, TFR may become an achievable goal for patients with CML-CP. ..
- Deep molecular response in chronic myeloid leukemia: the new goal of therapy?Francois Xavier Mahon
Authors Affiliations Laboratoire d Hématologie, Centre Hospitalier Universitaire de Bordeaux and Laboratoire Hématopoïèse Leucémique et Cible Thérapeutique, Biothérapies des maladies génétiques et cancers, Inserm U1035, Université Bordeaux Ségalen and Centre Régional de Lutte Contre le Cancer de Bordeaux et du Sud Ouest, Institut Bergonie, Departement d Oncologie Medicale, Bordeaux, France
Clin Cancer Res 20:310-22. 2014....
- Expression of the cell cycle regulators p14(ARF) and p16(INK4a) in chronic myeloid leukemiaMarie Cividin
Laboratoire d Hematologie, CHU de Poitiers, France
Leuk Res 30:1273-8. 2006..Although protein expression did not consistently match mRNA levels, a role for the two cell cycle regulators in the IFN-alpha signaling pathway is suggested as well as a relation with the resistance to IFN-alpha or imatinib therapy...
- Derivative (7)t(7;8)(q34;q21). a new additional cytogenetic abnormality in acute promyelocytic leukemiaJean Philippe Vial
Laboratoire d Hematologie, Centre Hospitalier et Universitaire de Bordeaux, Bordeaux, France
Cancer Genet Cytogenet 140:78-81. 2003..As the 7q and 8q breakpoints were similar in both cases, the involvement of these critical regions in the pathogenesis and outcome of APL disease has to be determined...
- Expression of interferon-alpha (IFN-alpha) receptor 2c at diagnosis is associated with cytogenetic response in IFN-alpha-treated chronic myeloid leukemiaC Barthe
, , 146, , 33076 Bordeaux Cedex, France
Blood 97:3568-73. 2001..0001). (Blood. 2001;97:3568-3573)..
- Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemiaM Pocaly
E0217 INSERM, Universite Victor Segalen Bordeaux 2, Hématopoïèse Leucémique et Cibles Thérapeutiques, Bordeaux Cedex, France
Leukemia 21:93-101. 2007..Moreover, the overexpression of Hsp70 detected in imatinib-resistant CML patients supports this mechanism and identifies potentially a marker and a therapeutic target of CML evolution...